Gastroesophageal Reflux Disease
📧 Sign up to get email alerts when something new happens for Gastroesophageal Reflux Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-12-21FDA Approved: PEPCID COMPLETE — Supplemental Application (Lil' Drug Store Products, Inc.)
FDA approved a supplemental application for Pepcid Complete, a chewable tablet that combines famotidine with calcium carbonate and magnesium…
-
CLINICAL_TRIALS trial_result · 2018-12-12Clinical Trial Update: The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease [Phase 4]
Phase 4 randomized trial comparing LINX device to double-dose PPI therapy for GERD has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-12-12Clinical Trial Update: Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets [Phase 4]
Phase 4 clinical trial comparing two rabeprazole formulations for gastroesophageal reflux disease has completed.
-
FDA approval · 2018-11-30FDA Approved: RABEPRAZOLE SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Rabeprazole SODIUM from Torrent Pharmaceuticals Limited.
-
FDA approval · 2018-11-27FDA Approved: LANSOPRAZOLE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original Abbreviated New Drug Application for lansoprazole from Zydus Pharmaceuticals USA Inc., enabling a generic version …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: Effect of Citalopram on Reflux Episodes in Healthy Volunteers [Phase 4]
Phase 4 trial assessing the effect of citalopram on reflux episodes in healthy volunteers.
-
CLINICAL_TRIALS trial_result · 2018-11-19Clinical Trial Update: A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients [Phase 3]
Phase 3 trial comparing E3810 at 10 mg once vs twice daily as maintenance therapy for PPI-resistant gastroesophageal reflux disease complete…
-
FDA approval · 2018-11-05FDA Approved: OMEPRAZOLE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for a generic omeprazole product. Omeprazole is a proton pump inhibitor indicated for gas…
-
FDA approval · 2018-09-27FDA Approved: RANITIDINE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s Original Application for ranitidine, a generic H2 blocker, with label indications including treatment …
-
FDA approval · 2018-08-20FDA Approved: RANITIDINE — Original Application (Granules India Ltd)
FDA approved Granules India Ltd's original application for ranitidine (generic). The product is intended for conditions such as duodenal and…
-
FDA approval · 2018-07-23FDA Approved: ESOMEPRAZOLE MAGNESIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc)
FDA approved Sun Pharmaceutical Industries, Inc.'s supplemental application for Esomeprazole Magnesium. This approval authorizes the marketi…
-
CLINICAL_TRIALS trial_result · 2018-07-23Clinical Trial Update: The Detection of Barrett's Esophagus by Gastrointestinal Endoscopy Prevents Esophageal Carcinoma in Morbid Obese After Sleeve Gastrectomy
This clinical trial evaluates whether detecting Barrett's esophagus via gastrointestinal endoscopy can prevent esophageal cancer in morbidly…
-
FDA approval · 2018-07-20FDA Approved: OMEPRAZOLE — Original Application (INNOVUS PHARMACEUTICALS, INC.)
FDA approved a generic version of omeprazole (omeprazole and omeprazole magnesium) under ANDA210593 from Innovus Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2018-07-19Clinical Trial Update: Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease [NA]
A completed clinical trial from Chinese PLA General Hospital evaluated endoscopic tri-modal imaging to differentiate Functional dyspepsia fr…
-
CLINICAL_TRIALS trial_result · 2018-07-13Clinical Trial Update: the Efficency and Safety of Stretta in GERD
Clinical trial update evaluating the efficacy and safety of the Stretta (radiofrequency ablation) system for gastroesophageal reflux disease…
-
CLINICAL_TRIALS research · 2018-06-26Clinical Trial Update: Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux
The trial investigating exhaled breath condensate pH in patients with cough caused by gastroesophageal reflux has been terminated.
-
CLINICAL_TRIALS trial_result · 2018-06-26Clinical Trial Update: Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose [NA]
This clinical trial update describes a response surface pathway design using two interventional variables and one response variable to estim…
-
CLINICAL_TRIALS trial_result · 2018-06-21Clinical Trial Update: Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis [Phase 1]
This clinical trial update reports on the prevalence and predictors of partial response to proton pump inhibitors in gastroesophageal reflux…
-
CLINICAL_TRIALS trial_result · 2018-06-15Clinical Trial Update: PK/PD Clinical Trial of YYD601 in Healthy Adult Male [Phase 1]
Completed Phase 1 PK/PD study of YYD601 in healthy adult males, evaluating pharmacokinetics and pharmacodynamics for gastroesophageal reflux…
-
FDA approval · 2018-06-12FDA Approved: BERKLEY AND JENSEN OMEPRAZOLE — Supplemental Application (BJWC)
FDA approved a supplemental application for BERKLEY AND JENSEN OMEPRAZOLE (omeprazole) submitted by BJWC.
-
FDA approval · 2018-06-07FDA Approved: PROTONIX DELAYED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for PROTONIX DELAYED-RELEASE (pantoprazole sodium) submitted by Wyeth Pharmaceuticals LLC (Pfize…
-
FDA approval · 2018-06-07FDA Approved: PREVACID — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for PREVACID (lansoprazole) filed by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2018-06-07FDA Approved: OMEPRAZOLE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for Omeprazole by Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2018-06-07FDA Approved: PROTONIX DELAYED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for PROTONIX DELAYED-RELEASE (pantoprazole sodium) submitted by Wyeth Pharmaceuticals LLC (Pfize…
-
FDA approval · 2018-06-07FDA Approved: OMEPRAZOLE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for omeprazole from Sandoz Inc, enabling the continued marketing of the generic omeprazole produ…